1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

Схожие документы

• MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
  по: Martin Reck, и др.
  Опубликовано: (2021)
• Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
  по: Zhang, Shannon S, и др.
  Опубликовано: (2021)
• P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
  по: Suresh S. Ramalingam, и др.
  Опубликовано: (2021)
• Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
  по: David Waterhouse, и др.
  Опубликовано: (2024)
• Sotorasib for Lung Cancers with KRAS p.G12C Mutation
  по: Skoulidis, F., и др.
  Опубликовано: (2021)